Investigating Potential Claims Against Altimmune: A Shareholder Alert by Faruqi & Faruqi

Shareholder Alert: Faruqi & Faruqi Investigates Claims on Altimmune

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims involving Altimmune, Inc., a company trading under the NASDAQ ticker ALT. This investigation is particularly focused on investors who incurred losses exceeding $75,000 during the period between August 10, 2023, and June 25, 2025. If you find yourself in this category, it is essential to understand your legal rights and available options.

What Led to the Investigation?

The basis for the investigation ties back to a significant incident that occurred on June 26, 2025, when Altimmune released the topline results from its IMPACT Phase 2b MASH trial concerning Pemvidutide, a treatment under development. Prior to this, there had been high expectations set by company executives, which invariably set the stage for disappointment. The company's claims of anticipated success were not matched by the results of the trial, which failed to achieve statistical significance regarding primary endpoints related to fibrosis reduction.

Altimmune's failure to meet these expectations is central to the claims being investigated. Even though there was a positive trend observed in the trial regarding fibrosis improvement, it fell short of statistical significance primarily due to an unexpectedly high placebo response, raising serious concerns and questions from both investors and analysts alike. Notably, during inquiries surrounding this result, company representatives downplayed the concerns, attributing the lack of expected results to the Phase 2 trial's early nature, suggesting that a Phase 3 trial would yield more favorable outcomes.

The Aftermath of the Release

The immediate financial repercussions were stark. After the unfavorable announcement, Altimmune’s stock price plummeted dramatically. From a closing price of $7.71 per share before the news broke, shares fell to $3.61 the following day, marking a staggering 53.2% decline. Such a drop not only affects current shareholders but poses serious questions about the company's future and its management's responsibilities.

In light of these events, Faruqi & Faruqi reminds investors that the deadline to seek the role of lead plaintiff in a recently filed federal securities class action against Altimmune is fast approaching on October 6, 2025. The lead plaintiff is typically an investor with a significant financial interest in the litigation and should share typical characteristics with other members of the affected group. While becoming a lead plaintiff might seem daunting, potential recoveries are not contingent upon this decision.

How to Get Involved

Faruqi & Faruqi encourages any shareholder or interested party who has pertinent information regarding Altimmune’s conduct to come forward. This includes whistleblowers, former employees, and other shareholders. If you suffered losses or have information relating to this situation, contacting Faruqi & Faruqi, LLP is a step toward uncovering your rights and potential claims.

For additional inquiries, you can reach out directly to partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). More information can also be accessed on their website at Faruqi & Faruqi.

Conclusion

In essence, this ongoing investigation aims to hold Altimmune accountable for the drastic losses inflicted upon its investors, raised by unmet expectations and inadequate communication from its management. As the class action develops, shareholders are urged to stay informed and proactive in safeguarding their financial interests.